胶质母细胞瘤患者的预后随时间显著改善:基于历史对照的探究
该回顾性分析纳入2005至2018年间在本中心按标准治疗(SOC)的722例新诊断胶质母细胞瘤(GBM)患者,年龄低于70岁、KPS高于70%,按诊断年份分为2005-2012年组和2013-2018年组。随访时间固定为24个月,组1中位总生存期(mOS)为19个月([17.3-21.3]),组2的mOS未达到;近期诊断与更长mOS显著相关(未校正HR=0.64,95%CI[0.51-0.81],p<0.001;校正后aHR=0.49,95%CI[0.36-0.67],p<0.001)。
要点
- 722例新诊断GBM患者按诊断年份分为2005-2012年组和2013-2018年组,随访固定24个月。
- 组1的mOS为19个月([17.3-21.3]),组2的mOS未达到。
- 近期诊断与更长mOS显著相关:未校正HR=0.64(95%CI[0.51-0.81]),校正后aHR=0.49(95%CI[0.36-0.67])。
核心结论
- 新诊断GBM患者的mOS随时间增加,可能与更好的非神经系统合并症管理、SOC优化、治疗副作用管理、支持治疗及参与临床试验有关。
研究设计与样本
- 回顾性分析722例新诊断GBM患者,年龄低于70岁、KPS高于70%,2005至2018年间在本中心按SOC治疗。
- 按诊断年份分组:组1为2005至2012年,组2为2013至2018年。
- 随访时间固定为24个月,以确保两组生存时间可比。
主要发现
- 两组在年龄、KPS、MGMT启动子甲基化状态和治疗等混杂因素方面非常相似。
- 组1的mOS为19个月([17.3-21.3]),组2的mOS未达到。
- 单因素分析显示近期诊断与更长mOS显著相关(HR=0.64,95%CI[0.51-0.81],p<0.001)。
- 多因素Cox分析显示校正混杂因素后诊断时期仍具显著预后价值(aHR=0.49,95%CI[0.36-0.67],p<0.001)。
临床怎么用
- 作者认为,GBM患者mOS随时间的增加可能与更好的非神经系统合并症管理、已验证SOC的优化、治疗副作用管理、支持治疗及参与临床试验有关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is the most common devastating primary brain cancer in adults. In our clinical practice, median overall survival (mOS) of GBM patients seems increasing over time. METHODS: To address this observation, we have retrospectively analyzed the prognosis of 722 newly diagnosed GBM patients, aged below 70, in good clinical conditions (i.e. Karnofsky Performance Status -KPS- above 70%) and treated in our department according to the standard of care (SOC) between 2005 and 2018. Patients were divided into two groups according to the year of diagnosis (group 1: from 2005 to 2012; group 2: from 2013 to 2018). RESULTS: Characteristics of patients and tumors of both groups were very similar regarding confounding factors (age, KPS, MGMT promoter methylation status and treatments). Follow-up time was fixed at 24 months to ensure comparable survival times between both groups. Group 1 patients had a mOS of 19 months ([17.3-21.3]) while mOS of group 2 patients was not reached. The recent period of diagnosis was significantly associated with a longer mOS in univariate analysis (HR=0.64, 95% CI [0.51 - 0.81]), p < 0.001). Multivariate Cox analysis showed that the period of diagnosis remained significantly prognostic after adjustment on confounding factors (adjusted Hazard Ratio (aHR) 0.49, 95% CI [0.36-0.67], p < 0.001). CONCLUSION: This increase of mOS over time in newly diagnosed GBM patients could be explained by better management of potentially associated non-neurological diseases, optimization of validated SOC, better management of treatments side effects, supportive care and participation in clinical trials.
引用
- Thomas-Joulié A, Tran S, El Houari L, et al. Prognosis of glioblastoma patients improves significantly over time interrogating historical controls. Eur J Cancer. 2024. PMID: 38493668. doi:10.1016/j.ejca.2024.114004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。